Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
Protocol ID
I3Y-MC-JPCS
Disease (Sub Disease)
Solid Tumours
Diagnosis Stage
Relapsed/refractory
Location
VIC, WA
Sponsor
Eli Lilly and Company
Links
Trial Status
Open
Sites
Perth Children's Hospital
Royal Children's Hospital
Royal Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
up to 21 Years
International registry ID's
NCT04238819
| Study Title | A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab GM-CSF Irinotecan and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C) |
|---|---|
| Protocol ID | I3Y-MC-JPCS |
| Disease (Sub Disease) | Solid Tumours |
| Diagnosis Stage | Relapsed/refractory |
| Location | VIC / WA |
| Sponsor | Eli Lilly and Company |
| Links | https://clinicaltrials.gov/ct2/show/NCT04238819 |
| Trial Status | Open |
| Trial Open Date | 09/11/2020 |
| Sites | Perth Children's Hospital/ Royal Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | up to 21 Years |
| International registry ID's | NCT04238819 |